ValuEngine lowered shares of InVitae (NYSE:NVTA) from a sell rating to a strong sell rating in a report released on Friday morning.

NVTA has been the topic of several other research reports. Zacks Investment Research downgraded InVitae from a hold rating to a sell rating in a research note on Thursday, January 4th. BidaskClub downgraded InVitae from a hold rating to a sell rating in a research note on Thursday, November 2nd. Benchmark cut their target price on InVitae from $16.00 to $11.00 and set a buy rating for the company in a research report on Tuesday, January 16th. Leerink Swann cut their target price on InVitae from $12.00 to $10.00 and set an outperform rating for the company in a research report on Tuesday, January 16th. Finally, Ladenburg Thalmann Financial Services began coverage on InVitae in a research report on Friday, January 5th. They set a buy rating and a $15.00 target price for the company. Three investment analysts have rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. The stock currently has an average rating of Hold and a consensus target price of $12.40.

InVitae (NYSE:NVTA) opened at $6.52 on Friday. The company has a debt-to-equity ratio of 0.33, a current ratio of 2.61 and a quick ratio of 2.61. InVitae has a 12 month low of $3.55 and a 12 month high of $10.41. The company has a market capitalization of $345.20, a PE ratio of -2.55 and a beta of 0.81.

InVitae (NYSE:NVTA) last posted its quarterly earnings data on Monday, November 6th. The medical research company reported ($0.57) EPS for the quarter, missing the consensus estimate of ($0.55) by ($0.02). InVitae had a negative return on equity of 115.25% and a negative net margin of 206.95%. research analysts expect that InVitae will post -2.53 EPS for the current fiscal year.

Large investors have recently added to or reduced their stakes in the stock. Lakeview Capital Partners LLC purchased a new stake in shares of InVitae during the third quarter worth about $117,000. Gabelli Funds LLC purchased a new stake in shares of InVitae during the third quarter worth about $131,000. State Board of Administration of Florida Retirement System purchased a new stake in shares of InVitae during the third quarter worth about $133,000. CAPROCK Group Inc. purchased a new stake in shares of InVitae during the third quarter worth about $139,000. Finally, Voya Investment Management LLC grew its position in shares of InVitae by 51.2% during the second quarter. Voya Investment Management LLC now owns 16,936 shares of the medical research company’s stock worth $162,000 after purchasing an additional 5,733 shares in the last quarter. Hedge funds and other institutional investors own 64.89% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “InVitae (NVTA) Cut to Strong Sell at ValuEngine” was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this report on another website, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark law. The legal version of this report can be accessed at https://www.thecerbatgem.com/2018/02/05/invitae-nvta-cut-to-strong-sell-at-valuengine.html.

InVitae Company Profile

Invitae Corporation utilizes an integrated portfolio of laboratory processes, software tools and informatics capabilities to process deoxyribonucleic acid (DNA)-containing samples, analyze information about patient-specific genetic variation and generate test reports for clinicians and their patients.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for InVitae Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InVitae and related companies with MarketBeat.com's FREE daily email newsletter.